Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LAMA/LABA

- PMLiVE

Benefits of AZ COVID-19 vaccine ‘continue’ to outweigh risks, says EMA’s executive director

EU regulator is expected to publish findings from its investigation on Thursday

- PMLiVE

AstraZeneca to supply US government with 500,000 additional doses of its COVID-19 antibody

AZD7442 is a long-acting antibody combination that could help to prevent and treat COVID-19

- PMLiVE

Safety review shows ‘no evidence’ that AZ’s vaccine causes increased risk of blood clots

AZ's vaccine continues to be backed by the EMA and the EMA’s Pharmacovigilance Risk Assessment Committee

- PMLiVE

EMA says there is ‘no indication’ AZ/Oxford’s COVID-19 vaccine causes blood clots

Agency’s safety committee added vaccine’s benefits continue to outweigh risks

- PMLiVE

GSK, Vir seek EUA after scoring positive results for COVID-19 antibody VIR-7831

VIR-7831 reduced the risk of hospitalisation/death by 85% in high-risk COVID-19 patients

- PMLiVE

Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s

Country's Health Ministry also recommended extending gap between doses to 12 weeks

- PMLiVE

GSK, Vir halt enrolment of phase 3 COVID-19 antibody study

Move comes after recommendation from independent data and safety monitoring board

- PMLiVE

First shipments of AZ/Oxford COVID-19 vaccine sent through COVAX

First COVAX shipments of vaccine dispatched to Ghana and Cote D’Ivoire

- PMLiVE

UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people

Data suggests vaccine is 80% effective at preventing hospitalisations in over-80s

- PMLiVE

AZ sells stake in Moderna for around $1.2bn

As Moderna expects COVID-19 vaccine sales to reach $18.4bn this year

- PMLiVE

AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population

Detailed results from the NAVIGATOR trial presented at virtual AAAAI meeting

- PMLiVE

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

Immunotherapy failed to hit primary endpoint in phase 3 DANUBE trial last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links